Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Feb 2026
Metabolic syndrome, rather than BMI or waist circumference, is linked to an increased likelihood of glaucoma and may better identify adults who could benefit from closer eye screening.
Read Full NewsThe recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.
1.
Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.
2.
Study identifies new approach to protect the brain during radiation therapy
3.
While most cancer screenings won't prolong lives, there are still good reasons to continue screening.
4.
Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.
5.
Radiation therapy for patients with breast cancer
1.
Radiation in Oncology: Advances, Applications, and Accessibility
2.
The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review
3.
Cracking Oncology Drug Resistance: New Strategies to Overcome Challenges in Modern Cancer Therapy
4.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
5.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
3.
Navigating the Complexities of Ph Negative ALL - Part XIII
4.
Navigating the Complexities of Ph Negative ALL - Part IV
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge